Teiko, Inc., a global CLIA-certified cytometry lab, today announced a collaboration with Zumutor Biologics, Inc. Zumutor has selected Teiko to provide its rapid, custom cytometry services, including panel development and high-throughput sample analysis, to support Zumutor's therapeutic pipeline.
Under the agreement, Teiko will first develop and verify a custom 42-marker mass cytometry panel specifically designed to meet Zumutor's research objectives for profiling cryopreserved peripheral blood mononuclear cells (PBMCs). Following the panel's verification, Teiko will process and analyze hundreds of PBMC specimens, providing comprehensive immune cell profiling and data analysis via its TokuProfile Dashboard.
This deep immunophenotyping will provide critical insights into the mechanism of action and pharmacodynamic effects of Zumutor's novel biologic candidates.
"Understanding the complex interactions between our therapeutic candidates and the immune system is critical to our development programs," said Maloy Ghosh, Chief Scientific Officer of Zumutor Biologics. "We selected Teiko for their ability to rapidly build and validate a working panel and their robust, end-to-end data analysis platform. The insights from this collaboration will be invaluable as we advance our first-in-class NK checkpoint therapeutic candidate ZM008."
"We are thrilled to partner with the innovative team at Zumutor Biologics," said Ramji Srinivasan, CEO of Teiko. "Our service is designed to deliver the high-resolution, actionable immune insights that are essential for accelerating the development of complex biologics like ZM008. We look forward to supporting the Zumutor team in their mission to bring new, effective treatments to patients."
Zumutor is a novel immuno therapeutics company driving transformational change by harnessing the power of NK cells in modulating the Tumor Micro Environment (TME). HQ'd in Boston, with labs in Bangalore, the company has developed a proprietary INABLR® platform consisting of multiple high diversity human antibody libraries, which are mined through a combination of yeast and phage display technologies.
Teiko is a global CLIA-certified cytometry lab for clinical trials. The company solves the problems translational scientists hate about flow cytometry on clinical trials: missing 20% of $1,000 blood specimens, lengthy panel builds, and bad gating. Teiko is working with groups like Genentech, Recursion, iOnctura, and dozens more to solve these problems.
For more information, visit www.teiko.bio.
.png)
